Clinical data supporting mechanism of action reinforce potential as a novel cancer treatmentBRISBANE, Calif., March 25, 2025 ...

One poster demonstrating cell-free DNA molecular response as a potential surrogate endpoint to measure clinical efficacy of azenosertib in ...

Only one in three adults in the U.S. are compliant with the new recommendation, and many still think 50 is the age for a ...

Context will present data highlighting the selection of the first-in-human dose of CT-95, using the minimal anticipated biological effect level (“MABEL”) approach, as required for immune agonist drugs ...

PHILADELPHIA and VANCOUVER, British Columbia, March 26, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, ...

Areas with elevated microplastic levels experience increased rates of hypertension, diabetes, stroke, and other ...

The abstracts will be available on the AACR 2025 meeting website. The posters will be available online at Erasca.com/science/presentations following the presentations.

Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ETCompany ParticipantsBruce Mackle - LifeSci Advisors, ...

Update on IND-enabling data for MP0712, a Radio-DARPin targeting DLL3 and labeled with 212Pb, co-developed with Orano Med; entering FIH studies in 2025 for the treatment of small cell lung cancer Firs ...

BioAtla is extending its runway beyond key clinical readouts in 1H 2026 by restructuring and realigning resources, which ...

Evaxion will present new biomarker and immune data obtained from the ongoing phase 2 trial. These will further add to EVX-01’s already strong clinical data package.

FROM nausea to constipation, we’ve all heard about the possible brutal side effects of fat jabs – but how familiar are you ...